Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics, Inc. is trading at $25.74, up 0.51% on the session. The 50 day average sits at $26.35 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 47.4, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $26.01 with resistance near $28.38, so that band frames the current range. Average daily movement is roughly $1.17, or about 4.5% of the share price, which is what any stop placement has to allow for. The overall health score of 51 out of 100 combines a trend score of 55, momentum of 38 and a risk score of 64.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.